EA201071315A1 - Ингибиторы протеазы вируса гепатита с - Google Patents

Ингибиторы протеазы вируса гепатита с

Info

Publication number
EA201071315A1
EA201071315A1 EA201071315A EA201071315A EA201071315A1 EA 201071315 A1 EA201071315 A1 EA 201071315A1 EA 201071315 A EA201071315 A EA 201071315A EA 201071315 A EA201071315 A EA 201071315A EA 201071315 A1 EA201071315 A1 EA 201071315A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepatitis
protease inhibitors
virus protease
compounds
virus
Prior art date
Application number
EA201071315A
Other languages
English (en)
Other versions
EA020235B1 (ru
Inventor
Чу-Чун Линь
Куан-Юань Ли
Йо-Чин Лю
Пинь Ло
Жун-Цзиунн Чэнь
Чэнь-Фу Лю
Чих-Мин Чэнь
Чи-Син Ричард Кинг
Original Assignee
Тайджен Байотекнолоджи Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тайджен Байотекнолоджи Ко., Лтд. filed Critical Тайджен Байотекнолоджи Ко., Лтд.
Publication of EA201071315A1 publication Critical patent/EA201071315A1/ru
Publication of EA020235B1 publication Critical patent/EA020235B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser

Abstract

Это изобретение относится к макроциклическим соединениям формулы (I) или (II), представленным в подробном описании. Эти соединения можно использовать для лечения инфекции вирусного гепатита С.
EA201071315A 2008-05-16 2008-11-04 Ингибиторы протеазы вируса гепатита с EA020235B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5385708P 2008-05-16 2008-05-16
PCT/US2008/082329 WO2009139792A1 (en) 2008-05-16 2008-11-04 Hcv protease inhibitors

Publications (2)

Publication Number Publication Date
EA201071315A1 true EA201071315A1 (ru) 2011-10-31
EA020235B1 EA020235B1 (ru) 2014-09-30

Family

ID=41316739

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071315A EA020235B1 (ru) 2008-05-16 2008-11-04 Ингибиторы протеазы вируса гепатита с

Country Status (15)

Country Link
US (1) US20090286814A1 (ru)
EP (1) EP2274281B1 (ru)
JP (1) JP5586588B2 (ru)
KR (2) KR20140048308A (ru)
CN (1) CN101580535B (ru)
AU (1) AU2008356226B2 (ru)
CA (1) CA2722056A1 (ru)
DK (1) DK2274281T3 (ru)
EA (1) EA020235B1 (ru)
ES (1) ES2542880T3 (ru)
HK (1) HK1148739A1 (ru)
NZ (1) NZ588189A (ru)
TW (1) TWI414306B (ru)
WO (1) WO2009139792A1 (ru)
ZA (1) ZA201008988B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2010005416A0 (en) 2008-04-15 2010-10-31 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication.
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US20110178107A1 (en) * 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
AU2011352145A1 (en) 2010-12-30 2013-07-18 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN102911254A (zh) * 2011-08-02 2013-02-06 上海唐润医药科技有限公司 Hcv蛋白酶抑制剂
ES2563479T3 (es) 2012-01-11 2016-03-15 Abbvie Inc. Procedimientos para elaborar inhibidores de proteasa de VHC
JP2015533124A (ja) 2012-10-08 2015-11-19 アッヴィ・インコーポレイテッド Ｈｃｖプロテアーゼ阻害剤を作製するのに有用な化合物
SG11201502802PA (en) 2012-10-19 2015-05-28 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
CN104557954A (zh) * 2013-10-16 2015-04-29 上海唐润医药科技有限公司 抗hcv的大环化合物
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
CN104447952A (zh) * 2014-12-11 2015-03-25 上海唐润医药科技有限公司 丙肝病毒蛋白酶抑制剂及其合成方法
CN105859748B (zh) * 2015-02-05 2018-06-08 爱博新药研发(上海)有限公司 多环化合物钠盐及其多晶型、制备方法及应用
WO2016127859A1 (en) * 2015-02-13 2016-08-18 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c inhibitors and uses thereof in medicine
CN107074876B (zh) * 2016-04-08 2019-12-20 上海长森药业有限公司 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途
CN107722109B (zh) * 2016-08-11 2020-12-18 广东东阳光药业有限公司 作为丙型肝炎病毒抑制剂的晶型
TW201805289A (zh) * 2016-08-11 2018-02-16 廣東東陽光藥業有限公司 作為丙型肝炎病毒抑制劑的鹽
CN110958880B (zh) * 2017-05-30 2023-08-08 东莞东阳光太景医药研发有限责任公司 固体分散制剂
CN113337624A (zh) * 2021-05-24 2021-09-03 温州医科大学 同时检测沙眼衣原体、淋病奈瑟氏球菌和解脲支原体的组合物及方法
CN114773302B (zh) * 2022-04-29 2024-04-02 中国药科大学 一种苯并呋喃衍生物及其医药用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4555508A (en) * 1984-03-02 1985-11-26 Usv Pharmaceutical Corp. Antihypertensive spiro-cyclic compounds
US5876984A (en) * 1996-09-25 1999-03-02 Shionogi & Co., Ltd Sequiterpene derivatives having antiviral activity
ZA9710927B (en) * 1996-12-06 1998-06-15 Fujisawa Pharmaceutical Co Pharmaceutical composition.
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
DE60217114T2 (de) * 2001-07-11 2007-10-25 Vertex Pharmaceuticals Inc., Cambridge Verbrückte bizyklische serinproteaseinhibitoren
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
AU2003207625B2 (en) * 2002-01-23 2006-09-07 Schering Corporation Proline compounds as NS3-serine protease inhibitors for use in treatment of hepatites C virus infection
US7119072B2 (en) * 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
PL213029B1 (pl) * 2002-05-20 2012-12-31 Bristol Myers Squibb Co Podstawiona pochodna cykloalkilowa, zawierajaca ja kompozycja oraz ich zastosowanie
ES2320771T3 (es) * 2003-04-16 2009-05-28 Bristol-Myers Squibb Company Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c.
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
UY28525A1 (es) * 2003-09-22 2005-04-29 Boehringer Ingelheim Int Péptidos macrociclicos activos contra en virus de la hepatitis c
WO2005030796A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Macrocyclic inhibitors of hepatitis c virus ns3 serine protease
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7253160B2 (en) * 2003-11-20 2007-08-07 Schering Corporation Depeptidized inhibitors of hepatitis C virus NS3 protease
WO2005058821A1 (en) * 2003-12-11 2005-06-30 Schering Corporation Inhibitors of hepatitis c virus ns3/ns4a serine protease
EP1730167B1 (en) * 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
EP1794178A1 (en) * 2004-09-17 2007-06-13 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic hcv protease inhibitors
US20070207949A1 (en) * 2005-06-02 2007-09-06 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
DK1919904T3 (da) * 2005-07-29 2014-04-07 Janssen R & D Ireland Makrocykliske inhibitorer af hepatitis-c-virus
WO2008022006A2 (en) * 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis c virus protease inhibitors
US7605126B2 (en) * 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US20080267917A1 (en) * 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
US20090111757A1 (en) * 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors

Also Published As

Publication number Publication date
EP2274281A4 (en) 2011-08-17
DK2274281T3 (en) 2015-07-20
US20090286814A1 (en) 2009-11-19
NZ588189A (en) 2012-08-31
AU2008356226B2 (en) 2012-04-12
WO2009139792A1 (en) 2009-11-19
AU2008356226A1 (en) 2009-11-19
TWI414306B (zh) 2013-11-11
ZA201008988B (en) 2012-01-25
EP2274281B1 (en) 2015-05-27
EA020235B1 (ru) 2014-09-30
CA2722056A1 (en) 2009-11-19
CN101580535A (zh) 2009-11-18
HK1148739A1 (en) 2011-09-16
JP5586588B2 (ja) 2014-09-10
CN101580535B (zh) 2012-10-03
EP2274281A1 (en) 2011-01-19
JP2011523411A (ja) 2011-08-11
KR20140048308A (ko) 2014-04-23
ES2542880T3 (es) 2015-08-12
TW200948375A (en) 2009-12-01
KR20110011663A (ko) 2011-02-08

Similar Documents

Publication Publication Date Title
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
EA201270423A1 (ru) Ингибиторы протеазы hcv
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
EA201270616A1 (ru) Ингибиторы вируса гепатита с
EA200901101A1 (ru) Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
EA201390190A1 (ru) Ингибиторы вируса гепатита с
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
EA201270656A1 (ru) Ингибиторы вируса гепатита с
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
DK1987038T3 (da) HCV NS5B-hæmmere
EA201101082A1 (ru) Ингибиторы вируса гепатита с
EA201001275A1 (ru) Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с
TW200833678A (en) HCV protease inhibitorscross reference
EA201171174A1 (ru) Ингибиторы репликации вируса гепатита c
EA201190224A1 (ru) Ингибиторы гепатита c, содержащие конденсированные кольца
ATE533771T1 (de) Cyclopropylkondensierte indolobenzazepine als hcv-ns5b-inhibitoren
EA201171208A1 (ru) Ингибиторы вируса гепатита с
EA201270622A1 (ru) Ингибиторы вируса гепатита с
NI200900069A (es) Inhibidores de la proteasa ns3 del hcv
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
WO2008057995A3 (en) Hcv protease inhibitors
EA200901241A1 (ru) Соединения для лечения гепатита с
EA201391152A1 (ru) Ингибиторы вируса гепатита с

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU